Unlike CAR-T therapy, which requires harvesting a patient’s cells, engineering them, and re-infusing them (a process that takes weeks), KBI-110 is an "off-the-shelf" biologic. It could be administered via IV infusion in a standard clinic day.
Mara screamed.